ClinicalTrials.gg
CompletedNCT02445326Updated Mar 29, 2018Results posted

OTX-14-007: A Phase 3 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Chronic Allergic Conjunctivitis

A Phase 3 interventional study of Dexamethasone and Placebo Vehicle in Chronic Allergic Conjunctivitis, sponsored by Ocular Therapeutix, Inc.. Completed. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-03-29.

Sponsored by Ocular Therapeutix, Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
73
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The objective of the study was to evaluate the efficacy and safety of OTX-DP (dexamethasone insert) 0.4 mg for intracanalicular use when placed in the canaliculus of the eyelid for the treatment of the signs and symptoms of chronic allergic conjunctivitis

02

Conditions studied

  • Chronic Allergic Conjunctivitis
03

In context

Conjunctivitis, Allergic

211 studies on the registry are indexed under Conjunctivitis, Allergic; 18 are open to participants now.

This study's enrollment of 73 is below the median of 87 across 174 interventional studies indexed under Conjunctivitis, Allergic.

Browse Conjunctivitis, Allergic studies →

Lead sponsor

Ocular Therapeutix, Inc. is the lead sponsor of 33 studies on the registry; 2 are open to participants now.

Of its 11 completed or terminated interventional studies of FDA-regulated products, 6 (55%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has a positive history of ocular allergies and a positive skin test reaction to a perennial allergen and a seasonal allergen
  • Has a positive bilateral CAC reaction to a perennial allergen within minutes of instillation

Exclusion criteria

Exclusion Criteria:

  • History of refractive surgery (including LASIK procedures)
  • History of retinal detachment, diabetic retinopathy, or active retinal disease
  • Presence of an active ocular infection or positive history of an ocular herpetic infection at any visit
  • Use any of the disallowed medications during the period indicated
  • History of IOP increase as a result of treatment
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
73 participants (actual)

Study arms

  • Experimental
    OTX-DP

    OTX-DP (dexamethasone insert) 0.4 mg for intracanalicular use

    Drug: Dexamethasone

  • Placebo comparator
    PV

    PV (placebo drug delivery vehicle)

    Other: Placebo Vehicle

Interventions

06

What researchers measure

Primary outcomes

  1. Ocular Itching Post-CAC (Conjunctival Allergen Challenge) at Visit 6

    Modified CAC model (Ora, Andover, MA); Grade 0-4, allowing half unit increments; 0=None

    Time frame: 3 minutes

  2. Ocular Itching Post-CAC (Conjunctival Allergen Challenge) at Visit 6

    Modified CAC model (Ora, Andover, MA); Grade 0-4, allowing half unit increments; 0=None

    Time frame: 5 minutes

  3. Ocular Itching Post-CAC (Conjunctival Allergen Challenge) at Visit 6

    Modified CAC model (Ora, Andover, MA); Grade 0-4, allowing half unit increments; 0=None

    Time frame: 7 minutes

  4. Conjunctival Redness Post-CAC (Conjunctival Allergen Challenge) at Visit 6

    Modified CAC model (Ora, Andover, MA); Grade 0-4, allowing half unit increments; 0=None

    Time frame: 7 minutes

  5. Conjunctival Redness Post-CAC (Conjunctival Allergen Challenge) at Visit 6

    Modified CAC model (Ora, Andover, MA); Grade 0-4, allowing half unit increments; 0=None

    Time frame: 15 minutes

  6. Conjunctival Redness Post-CAC (Conjunctival Allergen Challenge) at Visit 6

    Modified CAC model (Ora, Andover, MA); Grade 0-4, allowing half unit increments; 0=None

    Time frame: 20 minutes

07

Results

Posted Mar 29, 2018

Participant flow

Participant flow — Overall Study
MilestoneOTX-DPPlacebo Vehicle
Started3538
Completed3337
Not completed21

Outcome measures

PrimaryOcular Itching Post-CAC (Conjunctival Allergen Challenge) at Visit 6

Modified CAC model (Ora, Andover, MA); Grade 0-4, allowing half unit increments; 0=None

Time frame:
3 minutes
Reported as:
Mean · units on a scale
Ocular Itching Post-CAC (Conjunctival Allergen Challenge) at Visit 6
units on a scaleOTX-DPPlacebo Vehicle
Ocular Itching Post-CAC (Conjunctival Allergen Challenge) at Visit 61.68 ± 1.0322.66 ± 0.861
PrimaryOcular Itching Post-CAC (Conjunctival Allergen Challenge) at Visit 6

Modified CAC model (Ora, Andover, MA); Grade 0-4, allowing half unit increments; 0=None

Time frame:
5 minutes
Reported as:
Mean · units on a scale
Ocular Itching Post-CAC (Conjunctival Allergen Challenge) at Visit 6
units on a scaleOTX-DPPlacebo Vehicle
Ocular Itching Post-CAC (Conjunctival Allergen Challenge) at Visit 61.87 ± 1.0402.74 ± 0.690
PrimaryOcular Itching Post-CAC (Conjunctival Allergen Challenge) at Visit 6

Modified CAC model (Ora, Andover, MA); Grade 0-4, allowing half unit increments; 0=None

Time frame:
7 minutes
Reported as:
Mean · units on a scale
Ocular Itching Post-CAC (Conjunctival Allergen Challenge) at Visit 6
units on a scaleOTX-DPPlacebo Vehicle
Ocular Itching Post-CAC (Conjunctival Allergen Challenge) at Visit 61.70 ± 0.9382.74 ± 0.679
PrimaryConjunctival Redness Post-CAC (Conjunctival Allergen Challenge) at Visit 6

Modified CAC model (Ora, Andover, MA); Grade 0-4, allowing half unit increments; 0=None

Time frame:
7 minutes
Reported as:
Mean · units on a scale
Conjunctival Redness Post-CAC (Conjunctival Allergen Challenge) at Visit 6
units on a scaleOTX-DPPlacebo Vehicle
Conjunctival Redness Post-CAC (Conjunctival Allergen Challenge) at Visit 61.52 ± 0.6411.80 ± 0.764
PrimaryConjunctival Redness Post-CAC (Conjunctival Allergen Challenge) at Visit 6

Modified CAC model (Ora, Andover, MA); Grade 0-4, allowing half unit increments; 0=None

Time frame:
15 minutes
Reported as:
Mean · units on a scale
Conjunctival Redness Post-CAC (Conjunctival Allergen Challenge) at Visit 6
units on a scaleOTX-DPPlacebo Vehicle
Conjunctival Redness Post-CAC (Conjunctival Allergen Challenge) at Visit 61.48 ± 0.6981.75 ± 0.786
PrimaryConjunctival Redness Post-CAC (Conjunctival Allergen Challenge) at Visit 6

Modified CAC model (Ora, Andover, MA); Grade 0-4, allowing half unit increments; 0=None

Time frame:
20 minutes
Reported as:
Mean · units on a scale
Conjunctival Redness Post-CAC (Conjunctival Allergen Challenge) at Visit 6
units on a scaleOTX-DPPlacebo Vehicle
Conjunctival Redness Post-CAC (Conjunctival Allergen Challenge) at Visit 61.44 ± 0.7101.76 ± 0.766

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
OTX-DP0/35 (0%)0/35 (0%)3/35 (8.6%)
Placebo Vehicle0/38 (0%)0/38 (0%)4/38 (10.5%)
Most frequent other events
Most frequent other events
EventOTX-DPPlacebo Vehicle
Adverse EventsGeneral disorders3/354/38

Baseline characteristics

Age, Continuous
Age, Continuous(years)OTX-DPPlacebo VehicleTotal
Mean38.2 (19 to 66)36.3 (18 to 62)37 (18 to 66)
Sex: Female, Male
Sex: Female, Male(Participants)OTX-DPPlacebo VehicleTotal
Female171431
Male182442
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)OTX-DPPlacebo VehicleTotal
Hispanic or Latino369
Not Hispanic or Latino313162
Unknown or Not Reported112
Race (NIH/OMB)
Race (NIH/OMB)(Participants)OTX-DPPlacebo VehicleTotal
American Indian or Alaska Native000
Asian131124
Native Hawaiian or Other Pacific Islander000
Black or African American10919
White101222
More than one race022
Unknown or Not Reported246
Iris Color
Iris Color(Participants)OTX-DPPlacebo VehicleTotal
Blue415
Brown263258
Hazel101
Green459
08

Study locations

No study locations are listed for this record.

09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2015 to primary completion in Aug 2015, 4 months.

Results were first posted in Mar 2018, 2 years 7 months after primary completion.

Of 21 phase 3 interventional studies under Conjunctivitis, Allergic, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 14. This study's 4 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 13, 2015
First posted
May 15, 2015
StartActual
Apr 2015
Primary completionActual
Aug 2015
CompletionActual
Sep 2015
Results first posted
Mar 29, 2018
Last update
Mar 29, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 29, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02445326
Collaborators
ORA, Inc.
Responsible party
Sponsor
First posted
May 15, 2015
Start date
Apr 2015
Primary completion
Aug 2015
Completion
Sep 2015
Results posted
Mar 29, 2018
Last update
Mar 29, 2018
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexamethasone

Start the discussion